Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market.

ABSTRACT: This cross-sectional study describes changes in annual Medicare Part B spending for biologic drugs after biosimilar entry, focusing on the first 4 products to experience biosimilar competition: filgrastim, infliximab, epoetin alpha, and pegfilgrastim.

SUBMITTER: Dean EB 

PROVIDER: S-EPMC8796923 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature